Elon Musk said his biotech company Neuralink plans to begin high-volume production of its devices in 2026. He also said the company aims to shift to a fully automated surgical procedure in the same year.

Musk shared the update in a post on the social media platform X on Wednesday. He did not provide further details on production scale or automation timelines.

Neuralink did not immediately respond to a request for comment. The company develops brain-computer interface devices designed to be implanted in the human brain.

The implant is intended to help people with serious neurological conditions. These include spinal cord injuries that limit movement and communication.

The company’s first human patient has demonstrated several uses of the implant. The patient has used it to play video games, browse the internet, post on social media, and move a cursor on a laptop computer.

Neuralink began human trials of its brain implant in 2024. The trials followed earlier safety concerns raised by regulators in the United States.

The U.S. Food and Drug Administration had initially rejected the company’s application in 2022. Neuralink later addressed those concerns, allowing the trials to move forward.

In September, the company said 12 people worldwide with severe paralysis had received its implants. Neuralink said those patients were using the devices to control digital and physical tools through thought.

The company has not disclosed detailed clinical results from the trials. It has said the early focus remains on safety and functionality.

Neuralink also reported progress in securing funding. The company raised $650 million in a funding round completed in June.

Musk is the founder of several technology companies and has been a public advocate for brain-computer interface development. He has said such technology could eventually restore lost capabilities for people with neurological injuries.

The latest comments suggest Neuralink is preparing for a transition from experimental trials to scaled manufacturing. The move would mark a significant step in the company’s development as it works toward broader deployment of its implant technology.